What is claimed is:

1. A method of enhancing cardiac function in a patient having Fabry disease, the method comprising administering to the patient a formulation comprising an effective amount of migalastat or salt thereof every other day for enhancing the patient's cardiac function, wherein the effective amount is about 100 mg to about 150 mg free base equivalent (FBE).

2. The method of claim 1, wherein enhancing cardiac function comprises enhancing left ventricular systolic function.

3. The method of claim 1 or 2, wherein the patient has impaired midwall fractional shortening (MWFS) prior to initiating administration of the migalastat or salt thereof.

4. The method of any one of claims 1-3, wherein the migalastat or salt thereof enhances α-galactosidase A activity.

5. The method of any one of claims 1-4, wherein the patient is administered about 123 mg FBE of the migalastat or salt thereof every other day.

6. The method of any one of claims 1-5, wherein the patient is administered about 123 mg of migalastat free base every other day.

7. The method of any one of claims 1-5, wherein the patient is administered about 150 mg of migalastat hydrochloride every other day.

8. The method of any one of claims 1-7, wherein the formulation comprises an oral dosage form.

9. The method of claim 8, wherein the oral dosage form comprises a tablet, a capsule or a solution.

10. The method of any one of claims 1-9, wherein the migalastat or salt thereof is administered for at least 12 months.

11. The method of any one of claims 1-10, wherein the migalastat or salt thereof is administered for at least 24 months.

12. The method of any one of claims 1-11, wherein the patient is an enzyme replacement therapy (ERT)-naïve patient.

13. The method of any one of claims 1-12, wherein the administration of migalastat or a salt thereof provides an average increase in MWFS in a group of ERT-naïve patients with impaired MWFS of at least about 1% after 24 months of administration of migalastat or a salt thereof.

14. The method of any one of claims 1-11, wherein the patient is an ERT-experienced patient.

15. The method of any one of claims 1-14, wherein the patient has a HEK assay amenable mutation in α-galactosidase A.

16. The method of claim 15, wherein the mutation is disclosed in a pharmacological reference table.

17. The method of claim 16, wherein the pharmacological reference table is provided in a product label for a migalastat product approved for the treatment of Fabry disease.

18. The method of claim 16, wherein the pharmacological reference table is provided in a product label for GALAFOLD®.

19. The method of claim 16, wherein the pharmacological reference table is provided at a website.

20. The method of claim 19, wherein the website is one or more of www.galafoldamenabilitytable.com or www.fabrygenevariantsearch.com.

21. A method of increasing midwall fractional shortening (MWFS) in a patient having Fabry disease, the method comprising administering to the patient a formulation comprising an effective amount of migalastat or salt thereof every other day for increasing the patient's MWFS, wherein the effective amount is about 100 mg to about 150 mg free base equivalent (FBE).

22. The method of claim 21, wherein the patient has impaired MWFS prior to initiating administration of the migalastat or salt thereof.

23. The method of claim 21or 22, wherein the migalastat or salt thereof enhances α-galactosidase A activity.

24. The method of any one of claims 21-23, wherein the patient is administered about 123 mg FBE of the migalastat or salt thereof every other day.

25. The method of any one of claims 21-24, wherein the patient is administered about 123 mg of migalastat free base every other day.

26. The method of any one of claims 21-24, wherein the patient is administered about 150 mg of migalastat hydrochloride every other day.

27. The method of any one of claims 21-26, wherein the formulation comprises an oral dosage form.

28. The method of claim 27, wherein the oral dosage form comprises a tablet, a capsule or a solution.

29. The method of any one of claims 21-28, wherein the migalastat or salt thereof is administered for at least 12 months.

30. The method of any one of claims 21-29, wherein the migalastat or salt thereof is administered for at least 24 months.

31. The method of any one of claims 21-30, wherein the patient is an enzyme replacement therapy (ERT)-naïve patient.

32. The method of any one of claims 21-31 wherein the administration of migalastat or a salt thereof provides an average increase in MWFS in a group of ERT-naïve patients with impaired MWFS of at least about 1% after 24 months of administration of migalastat or a salt thereof.

33. The method of any one of claims 21-30, wherein the patient is an ERT-experienced patient.

34. The method of any one of claims 21-33, wherein the patient has a HEK assay amenable mutation in α-galactosidase A.

35. The method of claim 34, wherein the mutation is disclosed in a pharmacological reference table.

36. The method of claim 35, wherein the pharmacological reference table is provided in a product label for a migalastat product approved for the treatment of Fabry disease.

37. The method of claim 35, wherein the pharmacological reference table is provided in a product label for GALAFOLD®.

38. The method of claim 35, wherein the pharmacological reference table is provided at a website.

39. The method of claim 38, wherein the website is one or more of www.galafoldamenabilitytable.com or www.fabrygenevariantsearch.com.

40. A method of normalizing midwall fractional shortening (MWFS) in a patient having Fabry disease and impaired MWFS, the method comprising administering to the patient a formulation comprising an effective amount of migalastat or salt thereof every other day for normalizing the patient's MWFS, wherein the effective amount is about 100 mg to about 150 mg free base equivalent (FBE).

41. The method of claim 40, wherein the migalastat or salt thereof enhances α-galactosidase A activity.

42. The method of claim 40 or 41, wherein the patient is administered about 123 mg FBE of the migalastat or salt thereof every other day.

43. The method of any one of claims 40-42, wherein the patient is administered about 123 mg of migalastat free base every other day.

44. The method of any one of claims 40-42, wherein the patient is administered about 150 mg of migalastat hydrochloride every other day.

45. The method of any one of claims 40-44, wherein the formulation comprises an oral dosage form.

46. The method of claim 45, wherein the oral dosage form comprises a tablet, a capsule or a solution.

47. The method of any one of claims 40-46, wherein the migalastat or salt thereof is administered for at least 12 months.

48. The method of any one of claims 40-47, wherein the migalastat or salt thereof is administered for at least 24 months.

49. The method of any one of claims 40-48, wherein the patient is an enzyme replacement therapy) ERT-naïve patient.

50. The method of any one of claims 40-49, wherein the administration of migalastat or a salt thereof provides an average increase in MWFS in a group of ERT-naïve patients with

impaired MWFS of at least about 1% after 24 months of administration of migalastat or a salt thereof.

51. The method of any one of claims 40-50, wherein the patient has a HEK assay amenable mutation in α-galactosidase A.

52. The method of claim 51, wherein the mutation is disclosed in a pharmacological reference table.

53. The method of claim 52, wherein the pharmacological reference table is provided in a product label for a migalastat product approved for the treatment of Fabry disease.

54. The method of claim 52, wherein the pharmacological reference table is provided in a product label for GALAFOLD®.

55. The method of claim 52, wherein the pharmacological reference table is provided at a website.

56. The method of claim 55, wherein the website is one or more of www.galafoldamenabilitytable.com or www.fabrygenevariantsearch.com.

57. A method of stabilizing midwall fractional shortening (MWFS) in an enzyme replacement therapy (ERT)-experienced patient having Fabry disease, the method comprising administering to the patient a formulation comprising an effective amount of migalastat or salt thereof every other day for stabilizing the patient's MWFS, wherein the effective amount is about 100 mg to about 150 mg free base equivalent (FBE).

58. The method of claim 57, wherein the patient has impaired MWFS prior to initiating administration of the migalastat or salt thereof.

59. The method of claim 57 or 58, wherein the migalastat or salt thereof enhances α-galactosidase A activity.

60. The method of any one of claims 57-59, wherein the patient is administered about 123 mg FBE of the migalastat or salt thereof every other day.

61. The method of any one of claims 57-60, wherein the patient is administered about 123 mg of migalastat free base every other day.

62. The method of any one of claims 57-60, wherein the patient is administered about 150 mg of migalastat hydrochloride every other day.

63. The method of any one of claims 57-62, wherein the formulation comprises an oral dosage form.

64. The method of claim 63, wherein the oral dosage form comprises a tablet, a capsule or a solution.

65. The method of any one of claims 57-64, wherein the migalastat or salt thereof is administered for at least 12 months.

66. The method of any one of claims 57-65, wherein the migalastat or salt thereof is administered for at least 30 months.

67. The method of any one of claims 57-66, wherein the patient is an enzyme replacement therapy (ERT)-experienced patient.

68. The method of any one of claims 57-67, wherein the administration of migalastat or a salt thereof provides an average change in MWFS in a group of ERT-experienced patients with impaired MWFS of greater than about -0.5% after 30 months of administration of migalastat or a salt thereof.

69. The method of any one of claims 57-68, wherein the patient has a HEK assay amenable mutation in α-galactosidase A.

70. The method of claim 69, wherein the mutation is disclosed in a pharmacological reference table.

71. The method of claim 70, wherein the pharmacological reference table is provided in a product label for a migalastat product approved for the treatment of Fabry disease.

72. The method of claim 70, wherein the pharmacological reference table is provided in a product label for GALAFOLD®.

73. The method of claim 70, wherein the pharmacological reference table is provided at a website.

74. The method of claim 73, wherein the website is one or more of www.galafoldamenabilitytable.com or www.fabrygenevariantsearch.com.